Depsipeptide Nanostructure for Peptide Drug Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current peptide drugs face challenges due to poor in vivo pharmacokinetic properties, such as rapid hydrolysis, low bioavailability, and instability, which limits their efficacy and targeting efficiency.
Innovation Solution
A depsipeptide-based building block is developed, comprising a peptide for controlling drug release, a peptide for inhibiting protein-protein interactions (PPIs) with an α-helix secondary structure, and a cell-penetrating peptide, which forms a spherical nanostructure through self-assembly, enhancing stability and targeting efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If peptide drugs are used to inhibit protein-protein interactions, then PPI inhibition effect is achieved, but pharmacokinetic properties deteriorate due to rapid hydrolysis and low stability
Solution Approach 1:
The invention creates a composite nanostructure comprising a peptide drug (for PPI inhibition), a depsipeptide-based building block (for structural stability), and a cell-penetrating peptide (for cellular uptake). This composite approach combines the advantages of each component: the peptide provides target-specific inhibition, the depsipeptide provides structural stability and controlled release, and the cell-penetrating peptide enhances cellular internalization, thereby resolving the contradiction between PPI inhibition efficacy and pharmacokinetic stability
Solution Approach 2:
The nanostructure is designed with a bilayer membrane structure where the depsipeptide-based building blocks form a protective shell around the peptide drug. This flexible yet stable membrane protects the encapsulated peptide from premature hydrolysis in the bloodstream while allowing controlled release at the target site, thus improving pharmacokinetic stability without compromising the PPI inhibition effect
2Productivity
If peptide drugs are administered to achieve therapeutic effects, then in vitro activity is observed, but in vivo efficacy deteriorates due to rapid elimination and low bioavailability
Solution Approach 1:
The depsipeptide-based building block acts as an intermediary carrier that mediates between the peptide drug and the biological environment. It protects the peptide from rapid elimination by the kidneys, enhances blood-brain barrier penetration, and provides controlled release at the target site. This intermediary function bridges the gap between in vitro activity and in vivo efficacy by improving bioavailability and prolonging circulation time
Solution Approach 2:
The peptide drug is nested within the nanostructure formed by the depsipeptide-based building blocks. This nested configuration protects the active peptide component from degradation and elimination while allowing the outer shell to interact with biological systems, thereby maintaining in vitro activity levels and achieving reliable in vivo efficacy
3Ease of manufacture
If conventional encapsulation methods are used to deliver peptide drugs, then delivery is achieved, but loading efficiency deteriorates and nanostructural aggregation occurs
Solution Approach 1:
The depsipeptide-based building blocks possess self-assembling properties that enable them to spontaneously form stable nanostructures with the peptide drug without requiring complex external encapsulation processes. This self-service mechanism achieves 100% loading efficiency by incorporating the peptide drug into the nanostructure during self-assembly, while preventing aggregation through the stable bilayer membrane structure formed by the depsipeptide components
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The depsipeptide-based nanostructure achieves 100% loading efficiency, maintains secondary structure stability, and exhibits superior anticancer effects compared to conventional anticancer agents, with controlled pharmacodynamic properties and prolonged in vivo retention.
Implementation Method 1
forms a spherical nanostructure through self-assembly
Implementation Method 2
degraded by an esterase
Data Source
AI summary
An embodiment relates to a depsipeptide-based building block for inhibiting protein-protein interactions, a nanostructure including the same, and a use thereof, wherein the depsipeptide-based building block may remain in the body and cells for a long time when administered in vivo and be delivered to a target tissue with high efficiency, and a peptide for inhibiting protein-protein interactions may be gradually released over a long time to obtain a high effect.